Median overall survival was 105 months ( IQR 51-212 ) for 628 patients allocated ramucirumab plus docetaxel and 91 months ( 42-180 ) for 625 patients who received placebo plus docetaxel ( hazard ratio 086 , 95 % CI 075-098 ; p = 0023 ) .